EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression

• C. Antin,
• A. Tauziède-Espariat,
• M.-A. Debily,
• D. Castel,
• J. Grill,
• M. Pagès,
• O. Ayrault,
• F. Chrétien,
• A. Gareton,
• F. Andreiuolo,
• E. Lechapt,
• P. Varlet

Affiliations

C. Antin

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

A. Tauziède-Espariat

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

M.-A. Debily

UMR8203, Vectorologie et thérapeutiques anticancéreuses, CNRS, Gustave Roussy, Univ. Paris-Sud, Univ. Paris-Saclay

D. Castel

UMR8203, Vectorologie et thérapeutiques anticancéreuses, CNRS, Gustave Roussy, Univ. Paris-Sud, Univ. Paris-Saclay

J. Grill

UMR8203, Vectorologie et thérapeutiques anticancéreuses, CNRS, Gustave Roussy, Univ. Paris-Sud, Univ. Paris-Saclay

M. Pagès

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

O. Ayrault

CNRS UMR, INSERM, Institut Curie, PSL Research University

F. Chrétien

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

A. Gareton

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

F. Andreiuolo

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

E. Lechapt

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital

P. Varlet

Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital